[Treatment persistence and adherence with botulinum toxin type A and anti-calcitonin gene-related peptide monoclonal antibodies in migraine. (A retrospective cohort study from a specialized headache center)].

This study looked at how well migraine patients stick to treatments. It compared two options: botulinum toxin type A (BTA) and monoclonal antibodies targeting calcitonin gene-related peptide (anti-CGRP mAb). Researchers gathered data from 221 patients over a year. They defined treatment discontinuation as gaps between doses longer than 90 days for anti-CGRP mAb and 180 days for BTA. They used the Kaplan-Meier method to analyze treatment persistence. They also measured adherence using the Proportion of Days Covered (PDC), where 80% or more was considered high adherence. Results showed that both treatments had similar persistence and adherence rates among patients. This research is important for understanding how well patients follow through with these migraine treatments in real-world settings. It can help healthcare providers make better decisions about managing migraine therapies for their patients. Clinical relevance: This study highlights that both BTA and anti-CGRP mAb treatments have similar adherence rates, guiding clinicians in choosing effective migraine management options.